Year-end Sale % OFF 
Abstract
Introduction: The introduction of anti-HCV testing has been a milestone in medical history and markedly reduced transfusion-associated hepatitis C. Over the last 20 years, the performance of HCV antibody assays improved strikingly with sensitivities and specificities reaching >98% for most licensed tests. Still, a significant number of samples may yield borderline signal-to-cut-off ratios. Re-testing of samples and application of confirmatory recombinant blot assays or nucleic acid testing is time-consuming and costly. Moreover, false negative results should be avoided in particular in special risk groups such as immunocompromised patients. We here aimed to compare the performance of 4 licensed anti-HCV assays in samples with borderline signal-to-cut-off ratios obtained at a tertiary referral and transplant center.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
